A multicentre clinical trial led by a researcher from the University of Sherbrooke will test a new therapeutic approach to moderate asthma. The study will include 150 patients, including 50 in Quebec, ...

Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

Patients with chronic spontaneous urticaria (CSU) often experience impaired QOL, especially when antihistamines, the standard ...

New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, ...

We recently published 13 Best ADR Stocks to Invest In. Sanofi (NASDAQ:SNY) is one of the best ADR stocks. Sanofi (NASDAQ:SNY) ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these ...

EoE diagnosis is on the rise, and not all treatments have been successful. A Utah physician researcher explores how diet and the microbiome may influence inflammation and disease progression in this ...

A Chinese Phase IIb trial of the mAb has already started, with Mabwell also hoping to initiate a Phase IIa trial in the US.

In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which ...